All In Biotech

Drug Trial Radar · NCT06261957

A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

A Randomized, Double-blind, Parallel Group, Multi-center Study to Evaluate the Long-term Safety of Salbutamol Rescue Medication When Administered Via Metered Dose Inhalers Containing the Propellant HFA-152a or Reference HFA-134a

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 471 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

471

Actual

Start

May 31, 2024

Primary completion

Sep 2, 2025

Study completion Sep 2, 2025

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Feb 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged \>=18 years with asthma

Conditions

  • Asthma

Interventions

  • Salbutamol HFA-134aDrug

    100 microgram (μg) (ex-valve) at 30-second intervals per actuation

  • Salbutamol HFA-152aDrug

    100 μg (ex-valve) at 30-second intervals per actuation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) During Run-in PeriodTime frame: From Week -1 up to randomization (Day 1) during Run-in period
  2. Number of Participants With Adverse Events (AEs) During Treatment PeriodTime frame: From randomization (Day 1) up to Week 13 (Follow up) during treatment period

Locations

102 sites in 13 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    North Hollywood, California

  • GSK Investigational Site

    San Mateo, California

  • GSK Investigational Site

    Aventura, Florida

  • GSK Investigational Site

    Clearwater, Florida

  • GSK Investigational Site

    DeLand, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Naples, Florida

  • GSK Investigational Site

    Plantation, Florida

  • GSK Investigational Site

    Winter Park, Florida

  • GSK Investigational Site

    Rincon, Georgia

  • GSK Investigational Site

    Stonecrest, Georgia

  • GSK Investigational Site

    Louisville, Kentucky

  • GSK Investigational Site

    Owensboro, Kentucky

  • GSK Investigational Site

    Fall River, Massachusetts

  • GSK Investigational Site

    Minneapolis, Minnesota

  • GSK Investigational Site

    Minneota, Minnesota

  • GSK Investigational Site

    Olive Branch, Mississippi

  • GSK Investigational Site

    Columbia, Missouri

  • GSK Investigational Site

    Henderson, Nevada

  • GSK Investigational Site

    Jersey City, New Jersey

  • GSK Investigational Site

    Riverdale, New Jersey

  • GSK Investigational Site

    Brooklyn, New York

  • GSK Investigational Site

    Asheville, North Carolina

  • GSK Investigational Site

    Winston-Salem, North Carolina

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Dublin, Ohio

  • GSK Investigational Site

    Medford, Oregon

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Pottstown, Pennsylvania

  • GSK Investigational Site

    Rock Hill, South Carolina

  • GSK Investigational Site

    Spartanburg, South Carolina

  • GSK Investigational Site

    Spartanburg, South Carolina

  • GSK Investigational Site

    Union, South Carolina

  • GSK Investigational Site

    Sugar Land, Texas

  • GSK Investigational Site

    Tomball, Texas

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

Showing 40 of 102 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.